Comparative Pharmacology
Head-to-head clinical analysis: DECLOMYCIN versus DOXY 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECLOMYCIN versus DOXY 200.
DECLOMYCIN vs DOXY 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex, and thus inhibiting peptide chain elongation. It is bacteriostatic and active against a broad range of gram-positive and gram-negative bacteria, as well as atypical organisms.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
200 mg orally once daily or 100 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 40 hours).
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Renal: 40% unchanged via glomerular filtration; Biliary/fecal: 20–25% as active drug and metabolites; remainder as inactive metabolites.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic